SCHEMBL722154

SCHEMBL722154

CC(C)C(NP(=O)(Cl)Oc1cccc2ncccc12)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 5/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ADAMTS4 O75173 1/20 0.39
MMP13 P45452 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 1/20 0.38
NSD2 O96028 1/20 0.38
FABP5 Q01469 1/20 0.38
ALDH1A1 P00352 3/20 0.38
SCN9A Q15858 1/20 0.38
POLB P06746 1/20 0.37
PABPC1 P11940 1/20 0.37
EIF4H Q15056 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720108 0.89 MEN1 (0.40) NR3C1MEN1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL1744377 0.86 NR3C1 (0.39) NR3C1MEN1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL720708 0.83 L3MBTL1 (0.45) MEN1KMT2AL3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL721569 0.82 CASP3 (0.43) KMT2ASMN1; SMN2HSD17B10ALDH1A1KDM4E
SCHEMBL720417 0.80 SCN9A (0.38) NR3C1L3MBTL1SMN1; SMN2HSD17B10ALDH1A1
SCHEMBL720418 0.80 SCN9A (0.38) NR3C1L3MBTL1SMN1; SMN2HSD17B10ALDH1A1
SCHEMBL10208208 0.79 NR3C1 (0.39) NR3C1MEN1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL722003 0.77 ALDH1A1 (0.48) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL723660 0.75 CASP1 (0.37) NR3C1L3MBTL1SMN1; SMN2HSD17B10ALDH1A1
SCHEMBL723661 0.75 CASP1 (0.37) NR3C1L3MBTL1SMN1; SMN2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759318-B2 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections INHIBITEX, INC. (US) 2014-06-24 US disclosed
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2012-03-01 US disclosed
EP-2385951-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS University College Cardiff Consultants, Ltd. (GB) 2011-11-16 EP disclosed
US-20110254856-A1 MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL LG ELECTRONICS INC. (KR) 2011-10-20 US disclosed
WO-2010081082-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections PNP, SAMHD1, MTAP NR3C1 2166/4885MEN1 1740/4885KMT2A 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.